SCHEMBL1471569

SCHEMBL1471569

O=C1C=C(c2ccc(Cl)c(Cl)c2)C(=O)N1c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD51 Q06609 3/20 0.44
PPP1CA P62136 1/20 0.41
POLB P06746 1/20 0.41
HTT P42858 1/20 0.41
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40
HPGD P15428 2/20 0.40
ALOX12 P18054 2/20 0.40
CACNA1B Q00975 2/20 0.40
APBA1 Q02410 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
HCRTR1 O43613 1/20 0.40
S1PR4 O95977 1/20 0.40
LMNA P02545 1/20 0.40
HSP90AA1 P07900 1/20 0.40
S1PR1 P21453 1/20 0.40
BCL2A1 Q16548 1/20 0.40
ALKBH5 Q6P6C2 1/20 0.40
SRC P12931 2/20 0.39
AHR P35869 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471248 0.85 RAD51 (0.58) RAD51HTTALDH1A1MAPTHPGD
SCHEMBL1473349 0.83 MAPT (0.57) ALDH1A1MAPTHPGDALOX12CACNA1B
SCHEMBL303331 0.80 ALDH1A1 (0.51) HTTALDH1A1MAPTHPGDALOX12
SCHEMBL1471669 0.79 RAD51 (0.46) RAD51ALDH1A1MAPTHPGDALOX12
SCHEMBL17867651 0.78 MGLL (0.40) ALDH1A1MAPTHPGDALOX12CACNA1B
SCHEMBL934144 0.77 MGLL (0.53) HTTALDH1A1MAPTHPGDALOX12
SCHEMBL1471709 0.76 ALDH1A1 (0.47) RAD51HTTALDH1A1MAPTHPGD
SCHEMBL1471657 0.76 MAPT (0.54) ALDH1A1MAPTHPGDALOX12CACNA1B
SCHEMBL1471536 0.76 RGS4 (0.57) HTTALDH1A1MAPTHPGDALOX12
SCHEMBL7579280 0.75 MAPT (0.72) RAD51POLBHTTALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915304-B2 Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT CONGENIA S.R.L. (IT) 2011-03-29 US disclosed
EP-2091531-B1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S R L (IT) 2010-11-24 EP disclosed
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2010-04-22 US disclosed
EP-2091531-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT Congenia S.r.l. (IT) 2009-08-26 EP disclosed
WO-2008067863-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CYC1, MTPN, TXN2 RAD51 3231/4885PPP1CA 1106/4885POLB 3203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.